Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1][1][1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, marking a 5.95% increase year-on-year [1] - The net profit attributable to the parent company was 267 million RMB, representing a year-on-year growth of 19.17% [1] - Basic earnings per share stood at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable, with leading domestic brands increasing their market share [1] - The company actively adjusted its sales model and organizational structure, establishing a profit center system centered around professional departments to enhance marketing efficiency [1] - Product lines were further segmented, allowing for improved management and specialization within the sales team, leading to more precise clinical services and academic leadership in the market [1] - Focus on key surgical procedures through multi-product line collaborative sales resulted in significant growth in core hospital business, alongside increased efforts in developing lower-tier markets and promoting innovative products [1]

Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase year-on-year [1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, representing a 5.95% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a year-on-year growth of 19.17% [1] - Basic earnings per share were reported at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [1] - There is a further segmentation of product lines through detailed management by sales divisions, which aims to improve the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [1] - The company is concentrating on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]

Core Viewpoint - Weigao Orthopedics (688161.SH) reported a revenue of 1.539 billion yuan for the fiscal year 2025, marking a year-on-year growth of 5.95%, with a net profit attributable to shareholders of 267 million yuan, up 19.17% from the previous year [1] Financial Performance - The company achieved a net profit of 252 million yuan after deducting non-recurring gains and losses, reflecting a year-on-year increase of 19.59% [1] - Excluding share-based payment expenses, the net profit attributable to shareholders was approximately 296 million yuan, representing a growth of about 32.13% [1] - The net profit after excluding non-recurring gains and losses was around 281 million yuan, with a year-on-year increase of approximately 33.34% [1] Sales Strategy - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance sales organization vitality [2] - Product lines are further segmented through sales divisions, improving the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [2] - The company is focusing on key surgical procedures with multi-product line collaborative sales, leading to significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [2] Research and Development - The company maintains stable and continuous investment in R&D, increasing input in orthopedic biomaterials, intelligent devices, and minimally invasive consumables to drive innovation in the next generation of orthopedic products [2] - Ongoing efforts are made to promote the localization of raw materials for orthopedic consumables and improve R&D processes, gradually achieving quality enhancement and cost reduction [2] Production and Operations - The company is enhancing digital construction and building operational system platforms, significantly improving supply chain efficiency [2] - Through refined management, the company continues to reduce costs and increase efficiency, contributing to rapid growth in net profit [2]

Core Viewpoint - Weigao Orthopedics (688161.SH) reported a revenue of 1.539 billion yuan for the fiscal year 2025, marking a year-on-year growth of 5.95%, with a net profit attributable to shareholders of 267 million yuan, up 19.17% from the previous year [1] Group 1: Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 252 million yuan, reflecting a year-on-year increase of 19.59% [1] - After adjusting for share-based payment expenses of approximately 29 million yuan from the 2025 restricted stock incentive plan, the net profit attributable to shareholders was about 296 million yuan, representing a growth of approximately 32.13% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately 281 million yuan, with a year-on-year growth of about 33.34% [1] Group 2: Sales and Marketing Strategy - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [2] - There is a further segmentation of product lines through detailed management by sales divisions, improving the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [2] - The company is focusing on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [2] Group 3: Research and Development - The company maintains stable and continuous investment in R&D, increasing input in orthopedic biomaterials, intelligent devices, and minimally invasive consumables to drive innovation in the next generation of orthopedic products [2] - There is a continuous push for the localization of raw materials for orthopedic consumables and improvements in R&D processes to gradually achieve quality enhancement and cost reduction [2] Group 4: Production and Operations - The company is enhancing digital construction and building operational system platforms, significantly improving supply chain efficiency [2] - Through refined management, the company is continuously reducing costs and increasing efficiency, contributing to rapid growth in net profit [2]

山东威高骨科材料股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2026-005 | 归属于母公司的所 | 414,357.79 | 395,351.99 | 4.81 | | --- | --- | --- | --- | | 有者权益 | | | | | 股 本 | 40,000.00 | 40,000.00 | - | | 归属于母公司所有 | | | | | 者的每股净资产 | 10.36 | 9.88 | 4.81 | | （元） | | | | 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司 2025 年年度的定期报告为准。 3.数据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 本公告所载山东威高骨科材料股份有限公司（以下简称"公司"）2025年度 主要财务数 ...

Core Insights - Weigao Orthopedics reported a total operating revenue of 1.539 billion yuan for the fiscal year 2025, representing a year-on-year growth of 5.95% [1] - The net profit for the same period was 267 million yuan, reflecting a year-on-year increase of 19.17% [1] Sales and Market Strategy - The overall execution of volume-based procurement in orthopedics remained stable, with leading domestic brands continuing to increase their market share [1] - The company is actively adjusting its sales model and organizational structure, establishing a profit center system centered around professional departments to enhance marketing efficiency [1] - There is a focus on further segmenting product lines through detailed management by sales divisions, which aims to improve the professional capabilities and focus of the sales team for more precise clinical services and academic leadership in the market [1] - The company is concentrating on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in business from core hospitals [1] - Efforts are being made to develop lower-tier markets and promote innovative products, leading to a continuous increase in overall surgical volume, which contributes to sustained revenue and sales growth [1]

山东威高骨科材料股份有限公司 关于召开2026年第一次临时股东会的通知 证券代码：688161 证券简称：威高骨科 公告编号：2026-003 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2026年第一次临时股东会 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026年3月16日 至2026年3月16日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的9:15- 15:00。 （六）融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所科创板上市公司自律监管指引第1号一规范运作》等有关规定执行。 （七）涉及公开征集股东投票权 无 二、会议审议事项 本次股东会审议议案及投票股东类型 ● 股东会召开日期：2026年3月16日 ● ...

证券日报网讯 2月26日，威高骨科发布公告称，公司董事会提名陈敏、龙经、丛日楠、李进取、吕苏云 为非独立董事候选人，刘洪渭、孙建国、张海燕为独立董事候选人，预计2026年第一次临时股东会审议 通过后与职工代表董事共同组成第四届董事会，任期三年。 （文章来源：证券日报） ...

科创板上市公司独立董事候选人声明与承诺 本人张海燕,已充分了解并同意由提名人山东威高骨科材料 股份有限公司董事会提名为山东威高骨科材料股份有限公司第 四届董事会独立董事候选人。本人公开声明,本人具备独立董事 任职资格,保证不存在任何影响本人担任山东威高骨科材料股份 有限公司独立董事独立性的关系,具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、部门规章及其他规范性文件,具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定; (二)中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定; (三)中共中央纪委、教育部、监察部《关于加强高等学校 反腐倡廉建设的意见》的相关规定; (四)其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、本人具备独立性,不属于下列情形: (一)在上市公司或者其附属企业任职的人员及其直系亲属 和主要社会关系(直系亲属是指配偶、父母、 ...

科创板上市公司独立董事提名人声明与承诺 提名人山东威高骨科材料股份有限公司董事会,现提名张海 燕 为山东威高骨科材料股份有限公司第四届董事会独立董事候 选人,并已充分了解被提名人职业、学历、职称、详细的工作经 历、全部兼职、有无重大失信等不良记录等情况。被提名人已书 面 同 意 出 任 山 东 威 高 骨 科 材 料 股 份 有 限 公 司 第 四 届 董 事 会 独 立 董事候选人(参见该独立董事候选人声明)。提名人认为,被提 名人具备独立董事任职资格,与山东威高骨科材料股份有限公司 之间不存在任何影响其独立性的关系,具体声明并承诺如下; 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、 行政法规、规章及其他规范性文件,具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定; (二)中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定; (三)中共中央纪委、教育部、监察部《关于加强高等学校 反 ...